Euclises
Novel cox-2 inhibitors for the effective treatment of cancers in the lungs, colon, and pancreas.
Launch date
Employees
Market cap
-
Enterprise valuation
€4—7m (Dealroom.co estimates Dec 2016.)
St. Louis Missouri (HQ)
Authorizing premium user...